Mission Bio’s Tapestri Platform Unveils Insights into Targeted Therapy and Residual Disease Assessment for Multiple Myeloma
Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets
Mission Bio Announces High Precision Detection of Variants For Tapestri Platform
Mission Bio’s Tapestri Platform Leveraged by Top Academic and Pharma Institutions to Pinpoint Disease-Driving Clones in Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., June 13, 2023 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced today successful results of validation studies of the Tapestri® Platform. Data from a recently published white paper show how single-cell DNA sequencing technology could complement traditional bulk sequencing with the added advantage of detecting potential therapeutic resistance mutations.
SOUTH SAN FRANCISCO, Calif., May 11, 2023 /PRNewswire/ -- Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies.
SOUTH SAN FRANCISCO, Calif., Dec. 28, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers. The goal is to combine Mission Bio's industry-leading single-cell DNA and multi-omics capabilities with Abiosciences' cutting-edge artificial intelligence expertise, to uncover new disease signatures and address therapeutic resistance. These new capabilities can be leveraged in patient stratification for clinical trials and potentially, as a companion diagnostic tool.
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and multiple biopharma and academic partners are presenting data from the company's Tapestri® Platform on a range of topics at the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, beginning this weekend in New Orleans, LA. In all, Mission Bio and its partners will share 15 heme-oncology topics highlighting the use of single-cell DNA + protein multi-omics to better understand resistance mechanisms and drivers of relapse, improve identification of Measurable Residual Disease (MRD), and precisely characterize CAR T cell therapies. These include presentations from Servier Pharmaceuticals and researchers at Memorial Sloan Kettering Cancer Center (MSK) that demonstrate Tapestri's® ability to bridge the gap between translational research and precision therapeutics, providing a deeper understanding of the patient journey and unlocking novel therapeutic approaches. These include the following:
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis, today announced new data supporting the use of its Tapestri® Platform in clinical development, including clonal evolution patterns in patients with IDH1-mutated acute myeloid leukemia (AML) treated with Servier Pharmaceuticals' TIBSOVO (ivosidenib tablets) plus azacitidine. Data previously generated via single-cell DNA sequencing with Tapestri® supported analyses for Servier's ongoing pivotal phase 3 AGILE trial, the basis for U.S. Food and Drug Administration approval of the combination in newly diagnosed patients with IDH1-mutated AML in May 2022.